A

Advaxis Inc
F:FAD2

Watchlist Manager
Advaxis Inc
F:FAD2
Watchlist
Price: 0.0849 EUR -0.35% Market Closed
Market Cap: €12.4m

Net Margin

-434 785%
Current
Declining
by 140 928.1%
vs 3-y average of -293 856.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-434 785%
=
Net Income
$-48.1m
/
Revenue
$13k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-434 785%
=
Net Income
€-48.1m
/
Revenue
$13k

Peer Comparison

Country Company Market Cap Net
Margin
US
Advaxis Inc
F:FAD2
12.4m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 15 072 companies
1st percentile
-434 785%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Advaxis Inc
Glance View

Market Cap
12.4m EUR
Industry
Biotechnology

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.

FAD2 Intrinsic Value
Not Available
A
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-434 785%
=
Net Income
$-48.1m
/
Revenue
$13k
What is Advaxis Inc's current Net Margin?

The current Net Margin for Advaxis Inc is -434 785%, which is below its 3-year median of -293 856.8%.

How has Net Margin changed over time?

Over the last 3 years, Advaxis Inc’s Net Margin has decreased from -1 464.4% to -434 785%. During this period, it reached a low of -408 782.5% on Jan 31, 2024 and a high of -637% on Oct 31, 2021.

Back to Top